Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Geoffrey L. Uy, John F. DiPersio, Gerwin Huls et al.|Blood|2018Cited by 40
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaJie Wang, Bradley Sumrow, Adam S. Asch et al.|Blood|2020Cited by 25
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 ImmunotherapiesMichael P. Rettig, Jan Davidson‐Moncada, John E. Godwin et al.|Blood|2017Cited by 12
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasmsManish R. Patel, Susanna V. Ulahannan, Jason J. Luke et al.|Regular and Young Investigator Award Abstracts|2020Cited by 6